Literature DB >> 14682379

Imaging in gene therapy of patients with glioma.

A H Jacobs1, J Voges, L W Kracht, C Dittmar, A Winkeler, A Thomas, K Wienhard, K Herholz, W D Heiss.   

Abstract

Over 10 years ago, the first successful gene therapy paradigms for experimental brain tumors models have been conducted, and they were thought to revolutionize the treatment of patients with gliomas. Application of gene therapy has been quickly forced into clinical trials, the first patients being enrolled in 1994, with overall results being disappointing. However, single patients seemed to benefit from gene therapy showing long-term treatment response, and most of these patients bearing small glioblastomas. Whereas the gene therapy itself has been performed with high sophistication, limited attention has been paid on technologies, which (i) allow an identification of viable target tissue in heterogenous glioma tissue and which (ii) enable an assessment of successful vector administration and vector-mediated gene expression in vivo. However, these measures are a prerequisite for the development of successful gene therapy in the clinical application. As biological treatment strategies such as gene and cell-based therapies hold promise to selectively correct disease pathogenesis, successful clinical implementation of these treatment strategies rely on the establishment of molecular imaging technology allowing the non-invasive assessment of endogenous and exogenous gene expression in vivo. Imaging endogenous gene expression will allow the characterization and identification of target tissue for gene therapy. Imaging exogenously introduced cells and genes will allow the determination of the 'tissue dose' of transduced cell function and vector-mediated gene expression, which in turn can be correlated to the induced therapeutic effect. Only these combined strategies of non-invasive imaging of gene expression in vivo will enable the establishment of safe and efficient vector administration and gene therapy protocols for clinical application. Here, we review some aspects of imaging in gene therapy trials for glioblastoma, and we present a 'proof-of-principle' 2nd-generation gene therapy protocol integrating molecular imaging technology for the establishment of efficient gene therapy in clinical application.

Entities:  

Mesh:

Year:  2003        PMID: 14682379     DOI: 10.1023/b:neon.0000003658.51816.3f

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  55 in total

Review 1.  Molecular-genetic imaging: a nuclear medicine-based perspective.

Authors:  Ronald G Blasberg; Juri Gelovani
Journal:  Mol Imaging       Date:  2002-07       Impact factor: 4.488

2.  Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.

Authors:  A Jacobs; J G Tjuvajev; M Dubrovin; T Akhurst; J Balatoni; B Beattie; R Joshi; R Finn; S M Larson; U Herrlinger; P A Pechan; E A Chiocca; X O Breakefield; R G Blasberg
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

3.  Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas.

Authors:  A Jacobs; J Voges; R Reszka; M Lercher; A Gossmann; L Kracht; C Kaestle; R Wagner; K Wienhard; W D Heiss
Journal:  Lancet       Date:  2001-09-01       Impact factor: 79.321

4.  MR imaging and single-photon emission CT findings after gene therapy for human glioblastoma.

Authors:  F W Floeth; A Aulich; K J Langen; K J Burger; W J Bock; F Weber
Journal:  AJNR Am J Neuroradiol       Date:  2001-09       Impact factor: 3.825

5.  Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans.

Authors:  G Palù; A Cavaggioni; P Calvi; E Franchin; M Pizzato; R Boschetto; C Parolin; M Chilosi; S Ferrini; A Zanusso; F Colombo
Journal:  Gene Ther       Date:  1999-03       Impact factor: 5.250

6.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.

Authors:  J M Markert; M D Medlock; S D Rabkin; G Y Gillespie; T Todo; W D Hunter; C A Palmer; F Feigenbaum; C Tornatore; F Tufaro; R L Martuza
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

7.  Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence.

Authors:  A R MacLean; M ul-Fareed; L Robertson; J Harland; S M Brown
Journal:  J Gen Virol       Date:  1991-03       Impact factor: 3.891

8.  Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene.

Authors:  Z D Ezzeddine; R L Martuza; D Platika; M P Short; A Malick; B Choi; X O Breakefield
Journal:  New Biol       Date:  1991-06

9.  Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas.

Authors:  T Mineta; S D Rabkin; T Yazaki; W D Hunter; R L Martuza
Journal:  Nat Med       Date:  1995-09       Impact factor: 53.440

10.  MR of recurrent high-grade astrocytomas after intralesional immunotherapy.

Authors:  M M Smith; J E Thompson; M Castillo; S Cush; S K Mukherji; C H Miller; K B Quattrocchi
Journal:  AJNR Am J Neuroradiol       Date:  1996 Jun-Jul       Impact factor: 3.825

View more
  6 in total

Review 1.  Human gene therapy and imaging in neurological diseases.

Authors:  Andreas H Jacobs; Alexandra Winkler; Maria G Castro; Pedro Lowenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

2.  HMGA1 expression in human gliomas and its correlation with tumor proliferation, invasion and angiogenesis.

Authors:  Bo Pang; Haitao Fan; Ian Y Zhang; Bin Liu; Bin Feng; Lei Meng; Rui Zhang; Sam Sadeghi; Hua Guo; Qi Pang
Journal:  J Neurooncol       Date:  2011-10-08       Impact factor: 4.130

Review 3.  Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications.

Authors:  Y Waerzeggers; R T Ullrich; P Monfared; T Viel; M Weckesser; W Stummer; O Schober; A Winkeler; A H Jacobs
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 4.  Imaging in neurooncology.

Authors:  Andreas H Jacobs; Lutz W Kracht; Axel Gossmann; Maria A Rüger; Anne V Thomas; Alexander Thiel; Karl Herholz
Journal:  NeuroRx       Date:  2005-04

Review 5.  Advances in the treatment of primary brain tumors: dawn of a new era?

Authors:  Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2006-01       Impact factor: 5.075

Review 6.  Molecular therapies for malignant glioma.

Authors:  Markus Hutterer; Eberhard Gunsilius; Guenther Stockhammer
Journal:  Wien Med Wochenschr       Date:  2006-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.